QUEBEC CITY, May 10 /PRNewswire-FirstCall/ - Atrium Biotechnologies Inc. today announced that it is changing its name to Atrium Innovations Inc. The name change reflects the evolution from being the subsidiary of a biotechnology company to a leading multi product manufacturer and marketer as well as the increased recognition for having a diversified and innovative product portfolio. This new name demonstrates a global perspective and facilitates the creation of shareholder value through a new and clearer image of an integrated international company.
Board of Directors
Mr. Pierre Laurin, Chairman of the Board of Atrium Innovations, announced the appointment of Mrs. Carole St-Charles to the Board of Atrium Innovations. Mrs. St-Charles is the president of Consortium J.L.F. Inc., a limited partner of J.L Freeman LP which commercializes food and O.T.C. health care products. “We are delighted to be able to count on her pertinent business experience to pursue our strategic plan”, stated Pierre Laurin.
About Atrium
Atrium Innovations Inc. is a recognized leading developer, manufacturer and marketer of science-based products for the cosmetics, pharmaceutical, chemical and nutrition industries. The Company focuses primarily on growing segments of the health and personal care markets which are benefiting from the trends towards healthy living and the ageing of the population. Atrium markets a broad portfolio of active ingredients, specialty chemicals and health and nutrition finished products through its highly specialized sales and marketing network in more than 50 countries, primarily in North America, Europe and Asia. Atrium has over 560 employees and operates four manufacturing facilities. Additional information about Atrium is available on its Web site at www.atrium-bio.com.
Cautionary Note and Forward-Looking Statements
This press release contains certain forward-looking statements with respect to the Company. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by these forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable, but cautions the reader that these assumptions regarding future events, many of which are beyond its control, may ultimately prove to be incorrect since they are subject to risks and uncertainties that affect the Company. For additional information with respect to these and other factors, see the Company’s quarterly and annual filings with the Canadian securities commissions. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by law.
ATRIUM BIOTECHNOLOGIES INC.
CONTACT: Investor Relations: John Dempsey, Vice President, Finance andChief Financial Officer, (418) 652-1116, ext. 287, jdempsey@atrium-bio.com;Media Relations: Frederic Tremblay, HKDP, (514) 395-0375, ext. 234,ftremblay@hkdp.qc.ca; Source: Atrium Innovations Inc.
